GRI BIO INC
GRI · NASDAQ
Updated at 2026-10-14 09:34:49
- Today's High
- $1.60
- Today’s Low
- $1.52
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $1.75
- Previous Close
- $1.57
- Volume
- 64.73K
- Market Cap
- $3.43M
- P/E Ratio
- --
- EPS
- $-51.65
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, UNITED STATES, 92037
- Country
- US
- Listing Date
- 2021-02-10
- Fiscal Year End
- December
- Shares Outstanding
- 1.77M
- CIK
- 0001824293
- Website
- www.gribio.com
GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. By addressing the underlying causes of diseases rather than merely alleviating symptoms, GRI Bio aims to meet critical unmet medical needs with its transformative treatment options. The company has a strong pipeline of product candidates and actively engages in strategic collaborations to bolster its research initiatives. Positioned at the leading edge of the rapidly expanding microbiome therapeutics market, GRI Bio is dedicated to enhancing patient outcomes and has the potential to make significant contributions to the future of healthcare.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$6.33M
Operating Expenses
2026-06-30
$1.64M
2026-03-31
$2M
2025-12-31
$2.66M
2025-09-30
$3.36M
Net Income
2026-06-30
-$1.64M
2026-03-31
-$1.99M
2025-12-31
-$2.65M
2025-09-30
-$3.35M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
-53.03%
Earnings Per Share
2026-06-30
$-0.91
2026-03-31
$-1.61
2025-12-31
$-116.61
2025-09-30
$-35.84
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$1.64M
2026-03-31
-$2M
2025-12-31
-$2.66M
2025-09-30
-$3.36M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
-22.38%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.33M |
| Operating Expenses | $1.64M | $2M | $2.66M | $3.36M |
| Net Income | -$1.64M | -$1.99M | -$2.65M | -$3.35M |
| Net Profit Margin | -- | -- | -- | -53.03% |
| Earnings Per Share | $-0.91 | $-1.61 | $-116.61 | $-35.84 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$1.64M | -$2M | -$2.66M | -$3.36M |
| Effective Tax Rate | -- | -- | -- | -22.38% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.